Breast Augmentation — Cost, Top Hospitals & Success Rates | MyMedicPlus

Breast augmentation (augmentation mammaplasty) is the most commonly performed cosmetic surgical procedure worldwide — the International Society of Aesthetic Plastic Surgery (ISAPS) recorded approximately 1.8 million breast augmentation procedures globally in 2022. The procedure uses silicone gel or saline-filled implants, or in selected cases autologous fat transfer, to increase breast volume, improve breast shape and symmetry, and restore breast fullness lost after pregnancy, breastfeeding, or significant weight loss.

Modern breast implants are third-generation silicone gel devices with a thick, cohesive gel that maintains its shape even if the outer shell is breached ('gummy bear' implants), significantly improving on the liquid silicone implants associated with complications in the 1980s. Implants are classified by shell surface (smooth or textured), gel consistency (round or anatomical/teardrop-shaped cohesive gel), and size (measured in cubic centimetres of volume). The FDA-approved manufacturers (Allergan/Mentor/Sientra in the US; Eurosilicone/Sebbin/Motiva in Europe) produce implants with extensive long-term safety data.

Breast augmentation is performed by plastic surgeons in accredited surgical facilities. The surgical approach — incision site, implant pocket (submuscular vs. subglandular vs. dual-plane), and implant selection — is individualised based on the patient's anatomy (breast height, width, nipple position, skin quality, chest width), body proportions, lifestyle (high-impact sport — sub-muscular placement preferred), and aesthetic goals. Pre-operative 3D imaging (VECTRA 3D system or Crisalix digital simulation) allows the surgeon and patient to visualise simulated outcomes and select implant size.

Primary breast augmentation for aesthetic reasons — increasing breast volume in patients who feel their breasts are disproportionately small relative to their body frame (hypomastia or micromastia) — is the most common indication. Many patients describe significant self-consciousness and diminished self-confidence related to small breast size, with measurable impacts on body image, clothing choices, and interpersonal relationships. Breast augmentation consistently ranks among the highest satisfaction-rated cosmetic procedures in long-term patient-reported outcome studies.

Breast volume restoration is a distinct indication — women who have experienced significant breast volume loss and shape change after pregnancy and breastfeeding, after major weight loss, or as part of the involutional changes of the perimenopausal period commonly seek augmentation to restore their pre-pregnancy or pre-weight-loss breast appearance. Breast asymmetry — clinically significant size or shape difference between the two breasts, present as a natural variation in approximately 10–15% of women — can be corrected by augmenting one or both breasts to achieve symmetry, sometimes combined with a breast lift on the opposite side. Developmental breast anomalies including tuberous breast deformity (a congenital growth abnormality causing constriction of the breast base, high inframammary fold, and herniation of breast tissue into the areola) require specialised augmentation with simultaneous correction of the deformity.

Ideal candidates for breast augmentation are women aged 18 or older (22 or older for silicone gel implants in the US, per FDA guidance) who are in good general health, are non-smokers or are willing to stop smoking at least 4–6 weeks before surgery, have realistic expectations about the outcome, and are seeking the procedure for personal reasons rather than in response to pressure from others. A thorough pre-operative consultation includes breast examination, mammography or breast ultrasound (for women aged 35+ or those with a family history of breast cancer), discussion of implant options, and psychological assessment of motivations and expectations.

Contraindications include active breast infection or skin inflammation, untreated breast malignancy, autoimmune disease (relative contraindication — implants are safe in the large majority of autoimmune patients, though the MHRA and FDA advise careful counselling), pregnancy or breastfeeding (postpone until 6 months after breastfeeding is completed), current smoking, BMI above 30–35, and unrealistic expectations. Patients with a known BRCA1/BRCA2 mutation who are considering risk-reducing mastectomy should discuss whether augmentation or breast reconstruction is the most appropriate overall plan with their breast surgery team. Patients with a history of keloid or hypertrophic scarring should be counselled about scar outcomes at the incision sites.

The surgical approach to breast augmentation involves three key decisions: incision location, implant pocket plane, and implant selection. Incision locations include the inframammary fold (IMF) crease — the most common approach, providing excellent visibility and control, with the scar hidden in the natural breast fold; the periareolar approach (around the lower half of the areola), which minimises scar visibility in appropriately selected patients but carries a slightly higher risk of nipple sensation changes and implant contamination; and the transaxillary approach (through the armpit), which avoids any breast scar but provides less precise pocket control.

Implant pocket planes include subglandular (implant placed between breast gland and pectoral muscle), submuscular or dual-plane (partial or complete placement beneath the pectoralis major muscle). Submuscular/dual-plane placement provides additional soft tissue coverage of the upper implant pole — particularly important in thin patients with minimal natural breast tissue — and is strongly associated with lower rates of capsular contracture and superior mammographic visualisation. Round smooth silicone cohesive gel implants are the most commonly selected globally. Anatomical ('teardrop') textured implants provide a more natural slope but are associated with a very small risk of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) — a rare lymphoma linked specifically to textured implants — prompting MHRA and FDA regulatory guidance favouring smooth implants in most patients.

Fat transfer breast augmentation — using liposuction to harvest autologous fat from the abdomen, thighs, or flanks and re-injecting it into the breast — can achieve modest volume increase (0.5–1 cup size) without implants. It is appropriate for patients seeking subtle natural augmentation, those with implant concerns, or as an adjunct to implant augmentation to refine results. Multiple sessions may be required as approximately 50–70% of transferred fat survives long-term.

Breast augmentation has one of the highest patient satisfaction rates of any cosmetic surgical procedure. Systematic reviews and long-term cohort studies consistently report patient satisfaction rates of 85–95% at 5–10 years. Studies using validated quality-of-life and body image instruments (BREAST-Q, MOS SF-36) demonstrate significant improvements in sexual wellbeing, physical wellbeing, and self-confidence compared with pre-operative baseline, with effect sizes maintained at 5 and 10 year follow-up.

Modern cohesive gel implants have a dramatically improved safety profile compared with older implant generations. The FDA's 2019 long-term safety data (Core Study — Allergan and Mentor products) showed rupture rates of approximately 12–14% at 10 years (with silent intracapsular rupture detectable only on MRI), capsular contracture rates (Baker Grade III–IV — firm or painful breast) of approximately 15–20% at 10 years, and implant revision surgery rates of approximately 20–25% at 10 years. These statistics underscore that breast implants are medical devices that may require maintenance or replacement over a lifetime.

The most common complication of breast augmentation is capsular contracture — the normal scar tissue (capsule) that forms around the implant tightens excessively, causing breast hardness, distortion of shape, and in severe cases pain. Baker Grade III–IV capsular contracture affects approximately 10–15% of implants at 10 years and usually requires surgical capsulorrhaphy or implant exchange. Textured implant surfaces were developed to reduce capsular contracture rates but introduced the small risk of BIA-ALCL (breast implant-associated anaplastic large cell lymphoma), a rare T-cell lymphoma of the fluid or capsule around textured implants, with an estimated incidence of 1 in 3,000–30,000 patients with textured implants, treated by en bloc capsulectomy and implant removal (chemotherapy and radiotherapy reserved for advanced cases).

Implant rupture is typically silent (intracapsular — gel contained within the capsule) and detectable only by MRI surveillance recommended every 3–5 years. FDA guidance recommends regular surveillance imaging. Seroma, haematoma, infection, and implant malposition are early complications managed in the perioperative period. Changes in nipple sensation — increased or decreased — occur in approximately 10–15% of patients; most resolve within 6–12 months but can be permanent. Peri-prosthetic infection is uncommon (<1%) but may require implant removal in severe cases.

Breast augmentation is typically performed as a day procedure. Post-operative management includes a supportive surgical bra worn continuously for 4–6 weeks, avoidance of arm raising above shoulder height for 2 weeks, and gradual return to exercise over 4–6 weeks. Drains are not routinely used. Most patients return to sedentary work within 3–7 days and to normal daily activities within 2 weeks.

Post-operative visits are scheduled at 1 week (wound and implant check), 6 weeks (full activity clearance), 3 months (final assessment of shape and implant position), and annually thereafter. FDA recommends MRI surveillance at 5 years after silicone gel implant placement and every 2–3 years subsequently to screen for silent rupture. Patients should perform regular breast self-examination and attend routine breast screening as per age-appropriate guidelines — breast implants do not increase the risk of breast cancer but may require specialised implant-displacement mammography views (Eklund technique) to ensure adequate mammographic visualisation. Implants do not guarantee a lifetime of problem-free use — approximately 1 in 5 patients will require reoperation within 10 years for various implant-related reasons.

Breast augmentation costs vary significantly by implant brand, surgeon experience, facility quality, and geographic location. In the United States, breast augmentation costs USD 5,000–12,000 all-inclusive (surgeon, anaesthesia, implants, facility fee). In the United Kingdom, private breast augmentation costs GBP 3,500–7,000; NHS funding is not available for cosmetic augmentation. Australia, Canada, and Northern Europe have similar private cost ranges.

International breast augmentation — medical tourism — is heavily driven by cost savings. Turkey (Istanbul, Izmir) is the most popular destination, offering bilateral breast augmentation with CE-marked textured or smooth implants (Eurosilicone, Motiva) at USD 2,500–5,000 all-inclusive, approximately 50–65% lower than UK/US costs, performed at Joint Commission International (JCI) accredited hospitals. Thailand (Bumrungrad, Bangkok Hospital), India (Apollo, Fortis), Czech Republic, and Mexico are further high-quality, cost-effective destinations. Patients should verify that: (1) surgeon is a board-certified plastic surgeon; (2) implants are FDA or CE-marked (genuine Allergan, Mentor, Motiva — not counterfeit); (3) facility is accredited; and (4) a complete written record of the procedure and implant details is provided. Implant registration in the National Breast Implant Registry (where available) is advisable.

Fat transfer breast augmentation is the implant-free alternative for patients seeking modest volume increase (typically half to one cup size) without medical device implantation. It uses the patient's own tissue, avoids BIA-ALCL risk, and provides a very natural feel and appearance. The procedure requires adequate donor fat at harvest sites, multiple sessions may be needed, and a proportion of transferred fat is reabsorbed over time.

External tissue expanders (BRAVA device — an external suction bra worn for 10+ hours daily for months before fat transfer) may augment the recipient site for fat transfer in thin patients with minimal breast tissue, though patient compliance with this prolonged pre-treatment protocol is challenging. Non-surgical breast enhancement options — push-up bras, padding, posture improvement — provide non-permanent appearance improvement without surgical risk. Hormone therapy occasionally produces modest breast development in very young patients with pubertal delay, but it is not an option for adults seeking augmentation. For patients who require breast reconstruction after mastectomy, implant-based reconstruction, tissue expander-to-implant two-stage reconstruction, and autologous flap reconstruction (DIEP, TRAM, latissimus dorsi flap) are the available approaches, each with distinct advantages and considerations.